Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 412

1.

Repeat Rifaximin for Irritable Bowel Syndrome: No Clinically Significant Changes in Stool Microbial Antibiotic Sensitivity.

Pimentel M, Cash BD, Lembo A, Wolf RA, Israel RJ, Schoenfeld P.

Dig Dis Sci. 2017 Jun 6. doi: 10.1007/s10620-017-4598-7. [Epub ahead of print]

PMID:
28589238
2.

[Disaccharidase deficiency and functional bowel diseases].

Parfenov AI, Akhmadullina OV, Sabelnikova EA, Belostotsky NI, Kirova MV, Khomeriki SG, Bykova SV.

Ter Arkh. 2017;89(4):45-52. doi: 10.17116/terarkh201789445-52. Russian.

PMID:
28514399
3.

Small Intestinal Bacterial Overgrowth and Irritable Bowel Syndrome: A Bridge between Functional Organic Dichotomy.

Ghoshal UC, Shukla R, Ghoshal U.

Gut Liver. 2017 Mar 15;11(2):196-208. doi: 10.5009/gnl16126. Review.

4.

[Irritable bowel syndrome with constipation and functional constipation in adults: Treatment (Part 2 of 2)].

Mearin F, Ciriza C, Mínguez M, Rey E, Mascort JJ, Peña E, Cañones P, Júdez J; en nombre de la SEPD, la semFYC, la SEMERGEN y la SEMG.

Aten Primaria. 2017 Mar;49(3):177-194. doi: 10.1016/j.aprim.2017.01.003. Epub 2017 Feb 24. Spanish.

5.

[Irritable bowel syndrome with constipation and functional constipation in adults: Treatment (Part 2 of 2)].

Mearin F, Ciriza C, Mínguez M, Rey E, Mascort JJ, Peña E, Cañones P, Júdez J; en nombre de la SEPD, la semFYC, la SEMERGEN y la SEMG.

Semergen. 2017 Mar;43(2):123-140. doi: 10.1016/j.semerg.2017.01.001. Epub 2017 Feb 8. Spanish.

PMID:
28189496
6.

The Microbiome-Gut-Brain Axis in Health and Disease.

Dinan TG, Cryan JF.

Gastroenterol Clin North Am. 2017 Mar;46(1):77-89. doi: 10.1016/j.gtc.2016.09.007. Epub 2017 Jan 4. Review.

PMID:
28164854
7.

Progress with treating the microbial dysbiosis associated with irritable bowel syndrome.

Pearson JS, Whorwell PJ.

Curr Opin Gastroenterol. 2017 Jan;33(1):21-25. doi: 10.1097/MOG.0000000000000328.

PMID:
28134688
8.

[Efficacy analysis of fecal microbiota transplantation in the treatment of 406 cases with gastrointestinal disorders].

Li N, Tian H, Ma C, Ding C, Ge X, Gu L, Zhang X, Yang B, Hua Y, Zhu Y, Zhou Y.

Zhonghua Wei Chang Wai Ke Za Zhi. 2017 Jan 25;20(1):40-46. Chinese.

PMID:
28105618
9.

The Mexican consensus on probiotics in gastroenterology.

Valdovinos MA, Montijo E, Abreu AT, Heller S, González-Garay A, Bacarreza D, Bielsa-Fernández M, Bojórquez-Ramos MC, Bosques-Padilla F, Burguete-García AI, Carmona-Sánchez R, Consuelo-Sánchez A, Coss-Adame E, Chávez-Barrera JA, de Ariño M, Flores-Calderón J, Gómez-Escudero O, González-Huezo MS, Icaza-Chávez ME, Larrosa-Haro A, Morales-Arámbula M, Murata C, Ramírez-Mayans JA, Remes-Troche JM, Rizo-Robles T, Peláez-Luna M, Toro-Monjaraz EM, Torre A, Urquidi-Rivera ME, Vázquez R, Yamamoto-Furusho JK, Guarner F.

Rev Gastroenterol Mex. 2017 Apr - Jun;82(2):156-178. doi: 10.1016/j.rgmx.2016.08.004. Epub 2017 Jan 16. English, Spanish.

10.

Prevalence, Risk Factors, and Outcomes of Irritable Bowel Syndrome After Infectious Enteritis: A Systematic Review and Meta-analysis.

Klem F, Wadhwa A, Prokop LJ, Sundt WJ, Farrugia G, Camilleri M, Singh S, Grover M.

Gastroenterology. 2017 Apr;152(5):1042-1054.e1. doi: 10.1053/j.gastro.2016.12.039. Epub 2017 Jan 6. Review.

PMID:
28069350
11.

The comparison of treatments with and without azithromycin in irritable bowel syndrome with diarrhea-predominant in gastrointestinal Clinic of Al-Zahra Hospital, Isfahan, Iran.

Yazdani M, Aramesh A, Rafiei R, Daghaghzadeh H, Adibi P.

Adv Biomed Res. 2016 Nov 28;5:188. doi: 10.4103/2277-9175.192737. eCollection 2016.

12.

Can probiotics benefit children with autism spectrum disorders?

Navarro F, Liu Y, Rhoads JM.

World J Gastroenterol. 2016 Dec 14;22(46):10093-10102. doi: 10.3748/wjg.v22.i46.10093. Review.

13.

Factors Associated with Sequelae of Campylobacter and Non-typhoidal Salmonella Infections: A Systematic Review.

Esan OB, Pearce M, van Hecke O, Roberts N, Collins DR, Violato M, McCarthy N, Perera R, Fanshawe TR.

EBioMedicine. 2017 Feb;15:100-111. doi: 10.1016/j.ebiom.2016.12.006. Epub 2016 Dec 8. Review.

14.

Irritable bowel syndrome: a gut microbiota-related disorder?

Bhattarai Y, Muniz Pedrogo DA, Kashyap PC.

Am J Physiol Gastrointest Liver Physiol. 2017 Jan 1;312(1):G52-G62. doi: 10.1152/ajpgi.00338.2016. Epub 2016 Nov 23. Review.

PMID:
27881403
15.

Antimicrobial Susceptibility of Staphylococcus Isolates from the Skin of Patients with Diarrhea-Predominant Irritable Bowel Syndrome Treated with Repeat Courses of Rifaximin.

DuPont HL, Wolf RA, Israel RJ, Pimentel M.

Antimicrob Agents Chemother. 2016 Dec 27;61(1). pii: e02165-16. doi: 10.1128/AAC.02165-16. Print 2017 Jan. No abstract available.

16.

The Intestinal Microbiota in the Irritable Bowel Syndrome.

Collins SM.

Int Rev Neurobiol. 2016;131:247-261. doi: 10.1016/bs.irn.2016.08.003. Epub 2016 Sep 28.

PMID:
27793222
17.

Repeat Treatment With Rifaximin Is Safe and Effective in Patients With Diarrhea-Predominant Irritable Bowel Syndrome.

Lembo A, Pimentel M, Rao SS, Schoenfeld P, Cash B, Weinstock LB, Paterson C, Bortey E, Forbes WP.

Gastroenterology. 2016 Dec;151(6):1113-1121. doi: 10.1053/j.gastro.2016.08.003. Epub 2016 Aug 13.

18.
19.

Microbiome, antibiotics and irritable bowel syndrome.

Ahmad OF, Akbar A.

Br Med Bull. 2016 Dec;120(1):91-99. Epub 2016 Oct 13. Review.

PMID:
27737852
20.

[Chronic, non-infectious diarrhea: diagnostics and therapy].

Ulbricht K, Layer P, Andresen V.

Dtsch Med Wochenschr. 2016 Sep;141(19):1395-402. doi: 10.1055/s-0042-108700. Epub 2016 Sep 19. Review. German.

PMID:
27642742

Supplemental Content

Loading ...
Support Center